# Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer

> **NCT03238196** · PHASE1 · COMPLETED · sponsor: **Vanderbilt-Ingram Cancer Center** · enrollment: 35 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Erdafitinib
- **DRUG:** Palbociclib
- **DRUG:** Fulvestrant

## Key facts

- **NCT ID:** NCT03238196
- **Lead sponsor:** Vanderbilt-Ingram Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-18
- **Primary completion:** 2021-04-30
- **Final completion:** 2024-03-20
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2024-11-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03238196

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03238196, "Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03238196. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*